Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2009-09-29 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the completion of the acquisition of EBEWE Pharma by Sandoz, a division of Novartis, including details about the acquisition, integration plans, and forward-looking statements. There are no financial statements or detailed financial performance data included. The document serves as an announcement of a corporate transaction (acquisition) rather than a full merger filing or tender offer document. It is not an annual or interim report, earnings release, or management discussion. The document is a regulatory filing providing material information about a significant corporate event (acquisition) but does not fit the M&A Activity (TAR) or Merger & Acquisition (MA) categories which require more formal merger/tender offer filings. Given the nature and format, this is best classified as a Regulatory Filing (RNS).
2009-09-29 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing FDA approval for a new drug, Valturna, including detailed product information, clinical trial results, and company background. There are no financial statements, comprehensive financial performance data, or management discussion and analysis typical of annual or interim reports. The document is not a transcript, audit report, or governance-related filing. It is a regulatory announcement of a significant corporate event (FDA approval) communicated through a Form 6-K. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2009-09-21 English
Regulatory Filings 2009
Regulatory Filings
2009-09-16 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing clinical trial results for a drug (QAB149) and related information. There are no financial statements, detailed financial performance data, or comprehensive management discussion and analysis. The document is an announcement of new clinical data and corporate news rather than a financial report or regulatory filing with substantive financial data. It is not an earnings release, annual report, or interim report. The document is also not a certification or attestation. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2009-09-16 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release about clinical trial results for a vaccine, describing trial outcomes, tolerability, and future trial plans. It is a regulatory announcement providing information to investors and the SEC but does not contain comprehensive financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or management discussion. The document is a regulatory filing providing material information but not a full financial report or presentation. Therefore, it fits best under Regulatory Filings (RNS).
2009-09-04 English
4/A
Director's Dealing
2009-09-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.